Wadia Journal of Women and Child Health

Case Report

Water and the second se

A rare case of conservatively managed congenital chylothorax presenting as hydrops fetalis

Anand Subhash¹, R. R. Prashanth¹, Prathik Bandiya¹, Niranjan Shivanna¹

¹Department of Neonatology, Indira Gandhi Institute of Child Health, Bengaluru, Karnataka, India

*Corresponding author:

R. R. Prashanth, Department of Neonatology, Indira Gandhi Institute of Child Health, Bengaluru, Karnataka, India.

prash2635@gmail.com

Received: 01 November 2024 Accepted: 03 January 2025 Published: 15 March 2025

DOI 10.25259/WJWCH_44_2024

ABSTRACT

We report a term female neonate with non-immune hydrops fetalis with bilateral pleural effusion diagnosed as congenital chylothorax. Bilateral chest tube drainage is done and the neonate is successfully managed with measures including mechanical ventilation, medium chain triglyceride milk-based diet, and injection octreotide. A detailed course in the neonatal intensive care unit with a literature review on the management of congenital chylothorax has been included.

Keywords: Non-immune hydrops, Chylothorax, Pleural effusion

INTRODUCTION

Non-immune hydrops fetalis (NIHF) is a complication of congenital chylothorax occurring due to the accumulation of chyle. Overall, 753 such cases have been reported, with 68% of them being managed conservatively.^[1] The cause of this could be due to abnormalities of the lymphatic system, including lymphangiectasia, which is seen in 79% of cases.^[2]

CASE REPORT

A female neonate, born at 37 weeks to a 35-year-old mother with multiple gestation and nonconsanguineous union, had normal prenatal ultrasounds until the second trimester; further scans were not conducted. Delivery occurred through lower segment cesarean section due to a previous cesarean. The neonate did not cry immediately after birth and required extensive resuscitation, which included chest compressions and one dose of adrenaline. The APGAR scores were 2 and 4 at 1 and 5 min, respectively.

In the delivery room, the neonate was noted to have anasarca: Temperature: 98.6°F (36.5°C), heart rate: 170 beats per minute, respiratory rate: 76 breaths per minute, blood pressure: 60/42, mean 48 mmHg, and oxygen saturation: 65%. She was referred to our institution on bag and tube ventilation.

How to cite this article: Subhash A, Prashanth RR, Bandiya P, Shivanna N. A rare case of conservatively managed congenital chylothorax presenting as hydrops fetalis. Wadia J Women Child Health. 2024;3:141-5. doi: 10.25259/WJWCH_44_2024



This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. ©2024 Published by Scientific Scholar on behalf of Wadia Journal of Women and Child Health

Upon arrival, the neonate had respiratory distress, hypoxia, and shock, weighing 2500 g (with edema), measuring 43 cm (3^{rd} centile) in length and head circumference of 31.5 cm (3^{rd} centile), with anasarca, ascites and diminished air entry on both sides. There was no pallor, dysmorphic facies, or hepatosplenomegaly, and the cardiovascular assessment was unremarkable. The baby was stuporous, hypotonic and a depressed neonatal reflexes.

The baby was kept on mechanical ventilation and inotrope support. The blood group of both mother and neonate was O positive and direct coombs test (DCT) was negative.

Differential diagnoses for NIHF including chromosomal abnormalities (Monosomy X, Trisomy 21, or Trisomy 18), congenital lymphangiectasia, congenital lung malformation, congenital chylothorax, intrauterine infection, and cardiovascular disorders such as structural heart disease, cardiomyopathy, and fetal arrhythmias were considered.

The details of the evaluation of non-immune hydrops have been summarized in Table 1.

Chest X-ray and ultrasound revealed bilateral pleural effusion without any pericardial effusion [Figure 1]. Emergency pleural tapping was performed on both sides. Fifty milliliters of straw-colored fluid was aspirated from the left side and forty milliliters from the right side, after which a bilateral intercostal drainage (ICD) tube was inserted. This tube continued to drain straw-colored fluid, measuring 200 mL on the left side and 100 mL on the right side over the next 3 days [Figure 2]. The neonate was started on parenteral nutrition, including protein at 2 g/kg/day on day of life (DOL) 1, along with donor human milk and the mother's own milk, which was increased to 30 mL/kg/day. On DOL 5, the pleural effusion worsened, and the ICD fluid changed from straw colored to milky white, increasing in quantity [Figure 3].



Figure 1: X-ray showing bilateral pleural effusion (black arrows).

This issue was resolved upon changing the milk to mediumchain triglyceride (MCT)-based formula on DOL 7. The feed volume was gradually increased to 150 mL/kg/day with a targeted protein intake of at least 3.5–4 g/kg/day. Injection octreotide was considered due to persistently high mean airway pressure on ventilator and increasing ICD output over 4 days following which the ICD output significantly reduced. She also developed late-onset sepsis on DOL 3, which was managed with intravenous antibiotics. The neonate required high-frequency ventilation for the first 2 days, followed by conventional ventilation, and was removed from respiratory support by DOL 11. The baby achieved adequate weight gain from day 7 of life, and repeat blood counts and protein levels were normal.

The course in the hospital along with the details of pleural fluid cytology and biochemical analysis have been summarized in Table 2 [Figure 4].

Bilateral ICDs were removed on DOL-25 and discharged on MCT-based feeds. She is currently 48 days old and weighing 2900 g. Genetic testing is currently deferred for financial constraints and a magnetic resonance imaging brain is planned on follow-up.



Figure 2: Intercostal drainage showing thick straw color fluid suggesting lymphatic fluid.



Figure 3: Intercostal drainage showing milky chylous fluid (black arrow) upon introduction of human milk.

Table 1: Non-immune hydrops workup.		
Lab investigation	Patient value	Normal reference range
Complete blood count		
Hemoglobin (g %)	20.4	13.4-23.7
PCV (%)	57.6	45-65
MCV (fL)	112	90-112
MCH (pg)	39.3	32.5
MCHC (%)	35.1	32.1
RDW (%)	16.0	16.18±1.23
Retic count (%)	6%	0-1
Total leukocyte count (cells/mm ³)	24500	5000-20000
Platelet (lakhs/mm ³)	1.12	1.5-4.7
Peripheral smear	Normocytic, normochromic blood picture	
Blood group	O positive	
Bone marrow examination	Not done	
Direct comb test	Negative	
Blood culture	No growth	
Liver enzymes	C C	
SGOT (U/L)	62.3	9-80
SGPT (U/L)	12.1	13-45
Total proteins (g %)	3.3	6-7.5
Serum albumin (g %)	2.1	3–5
Serum Urea	28.0	
Serum Creatinine	0.7	
Serum ammonia (mcg/mL)	56	0.75-1.96
Serum lactate (mmol/L)	48	0.5-2.2
TSH (µIU/mL)	11	Up to 20
Total T4	6.47	
Free T4	1.54	
TORCH Titer	Negative	
Urine for proteins	Negative	
Skeletal survey	Normal	
Chest X-ray	Bilateral pleural effusion	
Echocardiography	Normal	
Cranial Ultrasound	Normal	
Ultrasound abdomen and KUB	Normal	
Ophthalmology evaluation	Normal	
Karyotype	44+xx	
OAE/AABR	Pass	

PCV: Packed cell volume, MCV: Mean corpuscular volume, MCH: Mean corpuscular hemoglobin, MCHC: Mean corpuscular hemoglobin concentration, RDW: Red cell distribution width, OAE: Otoacoustic emission, AABR: Automated auditory brainstem response, TSH: Thyroid-stimulating hormone, SGOT: Serum glutamic oxaloacetic transaminase, SGPT: Serum glutamic pyruvic transaminase, KUB: Kidney ureter bladder, TORCH: Toxoplasmosis, rubella, cytomegalovirus and herpes.

DISCUSSION

The loss of chyle, a major source of proteins including albumin, immunoglobin lymphocytes, and triglycerides, predisposes the neonate to extrauterine growth restriction and increased risk of sepsis as in the index neonate.^[3]

The management of such a neonate often starts in the labor room with antenatally detected cases being benefited by *ex utero* intrapartum treatment procedure and those diagnosed postnatally require extensive resuscitation and early chest tube drainage and mechanical ventilation including high-frequency oscillatory ventilation.^[4,5]

These neonates are at risk of shock secondary to hypovolemia necessitating adequate fluid resuscitation and the need to keep nil per oral and to decrease the further accumulation of chyle; this necessitates the initiation of total parenteral nutrition.^[6] The initial appearance of the chyle in the index case was clear straw-colored fluid and changed to a milky appearance after starting feeds. This is due to a progressive increase in the concentration of triglycerides in chyle in neonates who are fed. Availability of skimmed breast milk is a challenge and the use of MCTbased milk as the initial milk of choice in such neonates is an area of research interest.^[7]

Table 2: The course in the hospital.							
	DOL 1	DOL-3	DOL-5	DOL-8	DOL 11		
Hb (g%) TLC (cells/mm ³)	20.2 24.5	16 14.9	17.8 8.1	17.2 9.2	16.2 8.2		
Platelet (lakhs/mm³) Chest X-ray	1.12 Bilateral large pleural	1.05 Minimal bilateral effusion with ICD <i>in situ</i>	1.08	1.64	1.72 Minimal bilateral effusion with ICD <i>in situ</i> [Figure 4]		
ICD drain color	Yellow straw	Yellow straw	Milky white	Milky white	ICD drain –minimal straw colored		
Pleural fluid analysis	Cells-1360 All lymphocytes TG -34.8		Cells-5000 N-10 L-90 TG-182	Cell-1200 N-15 L-85			
S. Triglycerides (mg/dL)	46		133				
DOL: Day of life, Hb: Hemoglobin, TLC: Total leukocyte count, N: Neutrophils, L: Lymphocytes, ICD: Intercostal drainage, TG: Triglycerides, S.: Serum							



Figure 4: Chest X-ray showing improvement in bilateral pleural effusion at the time of discharge.

Octreotide decreases the secretion of pancreatic, biliary, and intestinal fluids; inhibits gallbladder contraction and gastrointestinal motility; and reduces splanchnic blood flow. Because of these physiological actions, octreotide may be used to lower portal pressure, fat absorption, and lymphatic flow in the thoracic duct in cases of congenital chylothorax. As in the index case, the use of octreotide is often limited to cases requiring prolonged mechanical ventilation (average 7 days) and its use safety, efficacy, and dosing regimens for neonatal patients with chylothorax need further studies.^[8]

Antenatal recognition of such cases often leads to better delivery room preparation. Antenatal interventions such as pleurodesis with injection OK 432 have shown promising short-term results.^[9,10]

Infants with chylothorax are at risk for hypoalbuminemia, electrolyte imbalances, clotting dysfunction, lymphopenia,

anemia, and immune deficiency due to chronic immunoglobulin loss, which increases the likelihood of infections. A study by Caserio *et al.* involving 29 infants (1990–2006) reported no recurrence, with most remaining asymptomatic, although 27% developed asthma early on. Follow-up at an average age of 7 years also showed no recurrence. Developmental outcomes in these infants are influenced by associated anomalies or severe prematurity.^[11,12]

This case highlights that a neonate diagnosed with NIHF, who typically experiences significant respiratory distress at birth along with bilateral pleural effusion and anasarca, should raise the possibility of congenital chylothorax. Both pleural tapping and ICD drainage are essential for diagnosing and treating these conditions. Initiating human milk feeds could exacerbate chylothorax, making MCT-based feeds a suitable alternative. It is crucial to anticipate and promptly manage sepsis and extrauterine growth restriction in these infants. The best approach for conservative management and avoiding surgery in such neonates includes parenteral nutrition, adequate ventilatory support, and octreotide to promote early recovery and discharge.

CONCLUSION

Congenital chylothorax requires a multidisciplinary approach to management. Nutritional considerations in neonates are paramount, particularly regarding the administration of breast milk and MCT-based formulas. Timely diagnosis and prompt treatment facilitate early discharge and ensure adequate growth in these neonates.

Ethical approval

Institutional Review Board approval is not required.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

REFERENCES

- 1. Resch B, Sever Yildiz G, Reiterer F. Congenital chylothorax of the newborn: A systematic analysis of published cases between 1990 and 2018. Respiration 2022;101:84-96.
- 2. Bialkowski A, Poets CF, Franz AR, Erhebungseinheit Für Seltene Pädiatrische Erkrankungen in Deutschland Study Group. Congenital chylothorax: A prospective nationwide epidemiological study in Germany. Arch Dis Child Fetal

Neonatal Ed 2015;100:F169-72.

- Attar MA, Donn SM. Congenital chylothorax. Semin Fetal Neonatal Med 2017;22:234-9.
- 4. Resch B. Management of congenital chylothorax of the newborn. Respiration 2022;101:795-6.
- Consigli C, Tempera A, Alegiani C, Spinelli M, Scapillati E, Haass C, *et al.* Ventilation mode and outcome of premature infants with congenital chylothorax. J Matern Fetal Neonatal Med 2012;25:1627-30.
- Healy H, Gipson K, Hay S, Bates S, Kinane TB. Management and outcomes of congenital chylothorax in the neonatal intensive care unit: A case series. Pediatr Investig 2017;1:21-25
- 7. Barbas KH. Mother's milk technicians: A new standard of care. J Hum Lact 2013;29:323-7.
- 8. Choo YM, Lim CT. Treatment of congenital chylothorax with octreotide in a hydropic preterm infant. Paediatr Int Child Health 2013;33:116-9.
- 9. Gregory CL, Wright J, Schwarz J, Rakowski L. A review of fetal thoracoamniotic & vesicoamniotic shunt procedures. J Obstet Gynecol Neonatal Nurs 2012;41:426-33.
- Leung VK, Suen SS, Ting YH, Law LW, Lau TK, Leung TY. Intrapleural injection of OK-432 as the primary in-utero treatment for fetal chylothorax. Hong Kong Med J 2012;18:156-9.
- Caserio S, Gallego C, Martin P, Moral MT, Pallas CR, Galindo A. Congenital chylothorax: From foetal life to adolescence. Acta Paediatr 2010;99:1571-7.
- 12. Chiang MC. Congenital chylothorax: Antenatal intervention, survival, and outcome. Pediatr Neonatol 2016;57:85-6.